GLP2-T
In Stock & Ready to Ship from USA
FREE shipping on orders over $200
Free BAC Water Included with Every Vial
Secure checkout via encrypted payment processor
Research Use Only
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Summary
GLP-2 Analog (Teduglutide) is a 33-amino acid analog of human glucagon-like peptide-2 (GLP-2) that has been studied for its effects on intestinal mucosal growth and nutrient absorption in preclinical models. This page is being updated with comprehensive research content.
GLP2-T — Research Data at a Glance
| Property | Value |
|---|---|
| Molecular Formula | C164H252N44O55 |
| Molecular Weight | 3752.1 Da |
| CAS Number | 197922-42-2 |
| Amino Acid Sequence | His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-A... |
| Contributing Researchers | 2 |
| Storage Conditions | Store refrigerated at 2–8°C. |
| Purity Standard | ≥99% (HPLC verified, 3rd-party COA) |
| Research Use Only | Not for human consumption. RUO only. |
Overview
GLP-2 Analog (Teduglutide) is a 33-amino acid analog of human glucagon-like peptide-2 (GLP-2) that has been studied for its effects on intestinal mucosal growth and nutrient absorption in preclinical models. This page is being updated with comprehensive research content.
Mechanism of Action
This page is being updated with comprehensive research content.
Research Applications
This page is being updated with comprehensive research content.
Biochemical Characteristics
| Property | Value |
|---|---|
| Formula | C164H252N44O55 |
| Molecular Weight | 3752.1 Da |
| Synonyms | Teduglutide, GLP-2 Analog, ALX-0600, Gattex, Revestive |
| Cas Number | 197922-42-2 |
| Sequence | His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp |
| Pubchem Cid | 16133828 |
| Monoisotopic Mass | N/A |
| Polar Area | N/A |
| Complexity | N/A |
| X Log P | N/A |
| Heavy Atom Count | N/A |
| H Bond Donor Count | N/A |
| H Bond Acceptor Count | N/A |
| Rotatable Bond Count | N/A |
Identifiers
| Pubchem Cid | |
|---|---|
| Inchi Key | |
| Inchi | |
| Smiles Isomeric | |
| Smiles Canonical | |
| Iupac Name |
Preclinical Research Summary
This page is being updated with comprehensive research content.
Authors & Attribution
✍️ Article Author
Dr. Ania M. Jastreboff
Ania M. Jastreboff, MD, PhD, is an Associate Professor of research compound (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale University School of research compound, and Director of the Y-Weight Yale Obesity Research Center. Dr. Jastreboff served as the lead investigator for the pivotal SURMOUNT-1 trial, which established tirzepatide’s efficacy for obesity research application (up to 22.5% weight reduction), and led the 3-year follow-up demonstrating significant metabolic outcomes. Her landmark papers in the New England Journal of research compound are among the most cited publications in obesity pharmacotherapy. Ania M. Jastreboff is being referenced as one of the leading scientists involved in the research and development of GLP-2 Analog (Teduglutide). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →🎓 Scientific Journal Author
Dr. Juan P. Frías
Juan P. Frías, MD, is a principal investigator at Velocity Clinical Research in Los Angeles, CA. Dr. Frías has been a lead investigator across the SURPASS clinical trial program for type 2 diabetes. He was the lead author on the landmark SURPASS-2 trial published in the New England Journal of research compound, which demonstrated tirzepatide’s superiority over semaglutide in both HbA1c reduction and weight loss. He also led early Phase 2 dose-finding studies that established the clinical proof of concept for dual GIP/GLP-1 receptor agonism. Juan P. Frías is being referenced as one of the leading scientists involved in the research and development of GLP-2 Analog (Teduglutide). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →Dr. Juan P. Frías is being referenced as one of the leading scientists involved in the research and development of GLP2-T. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
RUO Disclaimer
For Research Use Only (RUO). Not intended for human consumption, clinical use, or as a drug, food, cosmetic, or medical device. This product has not been evaluated by the FDA and is supplied solely for in-vitro laboratory research by qualified professionals.
Certificate of Analysis
Each lot is independently tested by accredited third-party laboratories (ISO 17025) at 99%+ purity.
Latest Lab Report
Storage & Handling
Summary
Store refrigerated at 2–8°C. Do NOT freeze. Room temp excursion: up to 30°C for 21 days max. Protect from light.
⚠️ Important: This product is a solution, not a lyophilized powder. Storage requirements differ from standard peptide powders.
❄️ Refrigerated Storage
Tirzepatide solution must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Store in the original carton to protect from light. Do not store in the refrigerator door to avoid temperature fluctuations.
🌡️ Room Temperature Excursion
Single-dose pens or vials may be stored unrefrigerated at temperatures not exceeding 30°C (86°F) for up to 21 days. If not used within this period, the product must be discarded. Multi-dose pens (where available) may have a use period of up to 30 days after first use.
❄️ Freezing
Do NOT freeze. If the solution has been frozen, it must not be used and should be discarded.
🧴 Handling Precautions
The solution should appear clear, colorless to slightly yellow. Do not use if the solution is cloudy, discolored, or contains particulate matter. Each vial is accompanied by a Certificate of Analysis (COA) detailing purity verification via RP-HPLC and Mass Spectrometry (MS). This product is for research use only (RUO).
Related Research Compounds
Cagriniltide
10mg
GLP3-R
60mg
GLP3-R
30mg